MV-005
Mucosal Infection (Undisclosed target)
PreclinicalActive
Key Facts
Indication
Mucosal Infection (Undisclosed target)
Phase
Preclinical
Status
Active
Company
About MV BioTherapeutics
MV BioTherapeutics is a private, preclinical-stage biotech leveraging novel microbiome-based platforms to develop therapeutics for enteric and systemic diseases. Its ApyraMed platform uses apyrase enzymes to improve intestinal fitness and immune competence, targeting inflammatory bowel disease and cancer. The ApyraVax platform is designed to elicit potent mucosal IgA responses against pathogens, positioning the company in the growing fields of microbiome therapeutics and mucosal vaccines.
View full company profile